TNFSF11 and cancer: Denosumab, an human monoclonal antibody specific for RANKL, inhibits the formation, activation, and survival of osteoclasts, decreasing bone resorption and reducing cancer-induced bone destruction [19], and is approved for the treatment of patients with osteoporosis, bone metastases and GCTBs.